Patents by Inventor Sharadha Subramanian

Sharadha Subramanian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biaryl amide compounds as kinase inhibitors
    Patent number: 10709712
    Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 14, 2020
    Assignee: NOVARTIS AG
    Inventors: Robert John Aversa, Paul Andrew Barsanti, Matthew T. Burger, Michael Patrick Dillon, Alan Dipesa, Cheng Hu, Yan Lou, Gisele A. Nishiguchi, Yue Pan, Valery Rostislavovich Polyakov, Savithri Ramurthy, Alice C. Rico, Lina Quattrocchio Setti, Aaron Smith, Sharadha Subramanian, Benjamin R. Taft, Huw Roland Tanner, Lifeng Wan, Naeem Yusuff
  • Compounds and compositions as kinase inhibitors
    Patent number: 10392404
    Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: August 27, 2019
    Assignee: Novartis AG
    Inventors: Paul Andrew Barsanti, Matthew T. Burger, Yan Lou, Gisele A. Nishiguchi, Valery Rostislavovich Polyakov, Savithri Ramurthy, Sharadha Subramanian, Benjamin R. Taft, Huw Rowland Tanner, Lifeng Wan
  • BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20190175606
    Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Application
    Filed: February 12, 2019
    Publication date: June 13, 2019
    Inventors: Robert John AVERSA, Paul Andrew BARSANTI, Matthew T. BURGER, Michael Patrick DILLON, Alan DIPESA, Cheng HU, Yan LOU, Gisele A. NISHIGUCHI, Yue PAN, Valery Rostislavovich POLYAKOV, Savithri RAMURTHY, Alice C. RICO, Lina Quattrocchio SETTI, Aaron SMITH, Sharadha SUBRAMANIAN, Benjamin R. TAFT, Huw Roland TANNER, Lifeng WAN, Naeem YUSUFF
  • Biaryl amide compounds as kinase inhibitors
    Patent number: 10245267
    Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: April 2, 2019
    Assignee: Novartis AG
    Inventors: Robert John Aversa, Paul Andrew Barsanti, Matthew T. Burger, Michael Patrick Dillon, Alan Dipesa, Cheng Hu, Yan Lou, Gisele A. Nishiguchi, Yue Pan, Valery Rostislavovich Polyakov, Savithri Ramurthy, Alice C. Rico, Lina Quattrocchio Setti, Aaron Smith, Sharadha Subramanian, Benjamin R. Taft, Huw Roland Tanner, Lifeng Wan, Naeem Yusuff
  • Compounds and compositions as RAF kinase inhibitors
    Patent number: 10167279
    Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: January 1, 2019
    Assignee: Novartis AG
    Inventors: Robert John Aversa, Matthew T. Burger, Michael Patrick Dillon, Thomas A. Dineen, Jr., Yan Lou, Gisele A. Nishiguchi, Savithri Ramurthy, Alice C. Rico, Vivek Rauniyar, Martin Sendzik, Sharadha Subramanian, Lina Quattrocchio Setti, Benjamin R. Taft, Huw Rowland Tanner, Lifeng Wan
  • COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS
    Publication number: 20180170917
    Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Application
    Filed: September 11, 2015
    Publication date: June 21, 2018
    Inventors: Robert John AVERSA, Matthew T. BURGER, Michael Patrick DILLON, Thomas A. DINEEN, Jr., Yan LOU, Gisele A. NISHIGUCHI, Savithri RAMURTHY, Alice C. RICO, Vivek RAUNIYAR, Martin SENDZIK, Sharadha SUBRAMANIAN, Lina Quattrocchio SETTI, Benjamin R. TAFT, Huw Rowland TANNER, Lifeng WAN
  • BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20170260207
    Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Application
    Filed: May 22, 2017
    Publication date: September 14, 2017
    Inventors: Robert John AVERSA, Paul Andrew BARSANTI, Matthew T. BURGER, Michael Patrick DILLON, Alan DIPESA, Cheng HU, Yan LOU, Gisele A. NISHIGUCHI, Yue PAN, Valery Rostislavovich POLYAKOV, Savithri RAMURTHY, Alice C. RICO, Lina Quattrocchio SETTI, Aaron SMITH, Sharadha SUBRAMANIAN, Benjamin R. TAFT, Huw Roland TANNER, Lifeng WAN, Naeem YUSUFF
  • COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
    Publication number: 20170260200
    Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Application
    Filed: September 11, 2015
    Publication date: September 14, 2017
    Inventors: Paul Andrew BARSANTI, Matthew T. BURGER, Yan LOU, Gisele A. NISHIGUCHI, Valery Rostislavovich POLYAKOV, Savithri RAMURTHY, Sharadha SUBRAMANIAN, Benjamin R. TAFT, Huw Rowland TANNER, Lifeng WAN
  • Biaryl amide compounds as kinase inhibitors
    Patent number: 9694016
    Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 4, 2017
    Assignee: NOVARTIS AG
    Inventors: Robert John Aversa, Paul Andrew Barsanti, Matthew Burger, Michael Patrick Dillon, Alan Dipesa, Cheng Hu, Yan Lou, Gisele Nishiguchi, Yue Pan, Valery Polyakov, Savithri Ramurthy, Alice Rico, Lina Setti, Aaron Smith, Sharadha Subramanian, Benjamin Taft, Huw Tanner, Lifeng Wan, Naeem Yusuff
  • Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors
    Patent number: 9546173
    Abstract: The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof; as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions. These are useful in the treatment of diseases such as cancer that are associated with activation of ERK1 and/or ERK2, and especially for MAPK pathway dependent cancers showing resistance to Raf and/or MEK inhibitory cancer therapeutics.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: January 17, 2017
    Assignee: Novartis AG
    Inventors: Michael Patrick Dillon, Mika Lindvall, Daniel Poon, Savithri Ramurthy, Vivek Rauniyar, Cynthia Shafer, Sharadha Subramanian, Huw Rowland Tanner
  • BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20160038504
    Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 11, 2016
    Applicant: NOVARTIS AG
    Inventors: Robert AVERSA, Paul A. BARSANTI, Matthew BURGER, Michael Patrick DILLON, Alan DIPESA, Cheng HU, Yan LOU, Gisele NISHIGUCHI, Yue PAN, Valery POLYAKOV, Savithri RAMURTHY, Alice RICO, Lina SETTI, Aaron SMITH, Sharadha SUBRAMANIAN, Benjamin TAFT, Huw TANNER, Lifeng WAN, Naeem YUSUFF
  • DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS
    Publication number: 20150274733
    Abstract: The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof; as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions.
    Type: Application
    Filed: September 17, 2013
    Publication date: October 1, 2015
    Applicant: NOVARTIS AG
    Inventors: Michael Patrick DILLON, Mika LINDVALL, Daniel POON, Savithri RAMURTHY, Vivek RAUNIYAR, Cynthia SHAFER, Sharadha SUBRAMANIAN, Huw TANNER
  • Substituted imidazole derivates
    Patent number: 8735599
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: May 27, 2014
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Weibo Wang, Paul A. Barsanti, Xia Yia, Rustum S. Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagnition, Ryan N. Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • Substituted benz-azoles and methods of their use as inhibitors of RAF kinase
    Patent number: 8614330
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: December 24, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Payman Amiri, Wendy Fantl, Teresa Hansen, Barry Haskell Levine, Christopher McBride, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Leonard Sung
  • Substituted benzimidazoles and methods of their use
    Patent number: 8592459
    Abstract: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: November 26, 2013
    Assignee: Novartis AG
    Inventors: Mina E. Aikawa, Payman Amiri, Jeffrey H. Dove, Barry Haskell Levine, Christopher McBride, Teresa E. Pick, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia Shafer, Darrin Stuart, Sharadha Subramanian
  • SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE
    Publication number: 20130224195
    Abstract: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Application
    Filed: April 3, 2013
    Publication date: August 29, 2013
    Inventors: Abran Costales, Teresa Hansen, Barry H. Levine, Christopher McBride, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Joelle Verhagen
  • Substituted benzazoles and methods of their use as inhibitors of RAF Kinase
    Patent number: 8415382
    Abstract: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: April 9, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Abran Costales, Teresa Hansen, Barry H. Levine, Christopher McBride, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Joelle Verhagen
  • SUBSTITUTED IMIDAZOLE DERIVATIVES
    Publication number: 20130017196
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 17, 2013
    Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagnition, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • Substituted imidazole derivatives
    Patent number: 8318791
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: November 27, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagniton, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE
    Publication number: 20120288501
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Application
    Filed: July 24, 2012
    Publication date: November 15, 2012
    Applicant: Novartis Vaccines and Diagnostics, Inc. formerly known as Chiron Corporation
    Inventors: Payman Amiri, Wendy Fantl, Barry Haskell Levine, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Sharadha Subramanian, Leonard Sung